Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT

Name: Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT
Published: 2023
License: Public Domain

Beijing Tsinghua Chang Gung Hospital · 2023

ClinicalTrials.gov · Datasets · License: Public Domain · 2023

Open Source ↗

hepatocellular-carcinoma

hepatocellular carcinoma, interventional, phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT

Related documents